4D Molecular Therapeutics (FDMT) Net Cash Flow Growth (3y) (2023 - 2026)
4D Molecular Therapeutics (FDMT) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -22.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.41% |
| Dec 31, 2025 | 30.23% |
| Sep 30, 2025 | -76.68% |
| Jun 30, 2025 | -51.87% |
| Mar 31, 2025 | 41.01% |
| Dec 31, 2024 | -37.79% |
| Sep 30, 2024 | 78.48% |
| Jun 30, 2024 | -75.09% |
| Mar 31, 2024 | 52.85% |
| Dec 31, 2023 | -28.89% |
| Sep 30, 2023 | 73.77% |
| Jun 30, 2023 | 33.56% |
| Mar 31, 2023 | 55.36% |